the placebo group – Page 6 – Communicable Diseases Research

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

단일 용량 Ad26.COV2.S의 효능 및 안전성에 대한 최종 분석

Clinical Trial

Published on 2022-03-032022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 임상,

Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial

중등도 COVID-19 감염으로 입원한 환자를 위한 글리시리진 및 보스웰산 병용 치료: 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-03-012022-09-10
Journal: Inflammopharmacology [Category] COVID19(2023년), SARS, 변종, 임상,

[키워드] Advancing Adverse adverse events age Anti-inflammatory Antiviral assigned Boswellic aids clinical clinical status Clinical status score Combination combination treatment COVID-19 death diagnosed double-blind drugs Efficacy eligibility eligible Enrollment evaluated event Evidence FIVE glycyrrhizin hospital hospitalized patient hospitalized patients Identifier immunomodulating Infection institutional protocol IQR matching placebo median median age Mild mild to moderate moderate Moderate COVID-19 moderate infection moderate symptoms Mortality mortality rate outcome Patient PCR test Placebo placebo group placebo-controlled Primary outcome Randomized randomized clinical trial randomized trial Randomly receive receiving recent Recovery time Registered required Safe SARS-CoV-2 secondary secondary outcome significant decrease significant difference significantly shorter single-center small sample size study drug Symptoms the placebo group therapeutic Time to recovery Treatment treatment of COVID-19 Trial university variant variants
[DOI] 10.1007/s10787-022-00939-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19

Research article

Published on 2022-03-012022-10-05
Journal: International Journal of Infectious Diseases [Category] SARS, 임상, 치료제,

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

중국 성인을 대상으로 한 SARS-CoV-2 ARCoV mRNA 백신의 안전성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1상 시험

Clinical Trial

Published on 2022-03-012022-09-11
Journal: The Lancet. Microbe [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] abnormal change abnormal changes Academy administration adverse event adverse events Adverse reaction Adverse reactions All participant All participants analyses Analysis Anti-RBD IgG anti-SARS-CoV-2 Antibody titre assigned baseline block Block randomisation caused cellular immune responses China Chinese clinical testing conducted convalescent patient Convalescent patients COVID-19 pandemic development domain dose dose-escalation doses double-blind effective vaccine Effective vaccines eligible participant ELISA ELISPOT ENCODE enrolled enzyme enzyme-linked immunospot expected exploratory Fever first vaccination FIVE foundation grade 3 group groups highest hospital humoral humoral immune responses Humoral response humoral responses IFN-γ IL-2 immune immune response immune responses immunogenicity incidence individual Intramuscular injection investigators Laboratory laboratory analyses Laboratory test Laboratory tests live SARS-CoV-2 lowest majority Medical Science Medical Sciences Mild moderate mRNA vaccine natural neutralisation assays Neutralising Antibodies neutralising antibody observation outcome participant Participants peaked Phase 1 phase 1 trial Placebo placebo group placebo-controlled Primary outcome pseudovirus randomised Randomly RBD RBD IgG RBD-specific IgG receive Registered reported research and development resolved Safe Safety safety analyses safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses Science screened second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events Seven significantly Specific Specific T-cell response Spike protein Support systemic adverse event T-cell Response T-cell responses the placebo group the SARS-CoV-2 titre titres Tolerability treatment allocation Trial vaccination Vaccine vaccine dose vaccine doses were assessed were given with COVID-19 Zhejiang
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

입원한 COVID-19 폐렴 환자에 대한 렌질루맙(LIVE-AIR): 3상, 무작위, 위약 대조 시험

Clinical Trial

Published on 2022-03-012022-09-12
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단,

[키워드] 1:1 95% CI added Administered Adverse adverse event age assigned baseline Brazil C-reactive protein concentration cardiac disorder contribute Corticosteroids COVID-19 criteria CTCAE cytokine death demographics disease severity dose double-blind Efficacy and safety enrolled event GM-CSF granulocyte-macrophage colony-stimulating factor greater groups hazard ratio hospitalised hospitalised patient hyperinflammation Immune-mediated immunomodulator include Inflammatory intention-to-treat population intravenous dose Invasive mechanical ventilation investigated investigator IQR likelihood males median mITT mITT analysis modified intention-to-treat monoclonal antibody neutralising participant pathophysiology Patient patients with COVID-19 Phase 3 Placebo placebo-controlled trial Pneumonia primary endpoint Primary outcome randomisation randomised Randomly receive recruited Registered Remdesivir respiratory disorder Respiratory failure safety profile screened severity significantly standard supportive care steroid stratified study drug survival the placebo group treat treating COVID-19 treatment-emergent adverse event Trial USA were assessed with COVID-19
[DOI] 10.1016/S2213-2600(21)00494-X PMC 바로가기 [Article Type] Clinical Trial

Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)

중등도 내지 중증의 코비드 -19 폐렴의 치료에서의 회복기 혈장 : 무작위 대조 시험 (보호 환자 시험)

Clinical Trial

Published on 2022-02-152022-09-01
Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, 치료제,

[키워드] 1:1 95% CI anti-SARS-CoV-2 antiviral activity benefit blueprint clinical Clinical improvement Clinical trial design clinical trials clinically contribute Controlled trial convalescent plasma convalescent plasma group COVID-19 COVID-19 pneumonia COVID-19 severity Data and Safety Monitoring Board double-blinded effective therapy Efficacy enrolment Evidence feasibility futility Grade 1 HIV HIV positive hospital hospital discharge hospitalized patient hospitalized patients improvement indications individuals investigated median moderate multicenter neutralizing antibody Non-invasive observational studies observational study occurred Ordinal Scale oxygen participant Participants performed placebo group plasma Pneumonia Premature Prevalence Primary outcome primary outcome measure public sector Randomized Randomized controlled trial Randomized controlled trials receive recommendation reducing Relative risk risk Safety Safety Monitoring Board saline solution scale severe COVID-19 South Africa suggested Support the placebo group therapeutic option titre transfusion-related adverse event Treatment Trial with COVID-19 World Health Organisation
[DOI] 10.1038/s41598-022-06221-8 PMC 바로가기 [Article Type] Clinical Trial

Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial

COVID-19 감염이있는 회복기 환자 관리에서 Bufei Huoxue 캡슐의 효능 및 안전성 : 다중 센터, 이중 맹검 및 무작위 대조 시험

Randomized Controlled Trial

Published on 2022-02-102022-08-31
Journal: Journal of ethnopharmacology [Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] adverse event adverse events assessment attenuate baseline Bufei Huoxue capsules Chest computed tomography Chest CT China Chinese Chinese Materia Medica Computed tomography Controlled trial convalescent patient coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescence COVID-19 infection double-blind Effect Efficacy Efficacy and safety estimate evaluate exclusion Exercise Tolerance exhibited fatigue functional Functional status greater IMPROVE improvement Improvements indicated inventory management manifestation materia medica medications multicentre multiple organs not significant Patient physiological Placebo placebo group Pneumonia pneumonia lesion pneumonia lesions Previous studies previous study Primary outcome Primary outcomes randomised controlled trial randomly divided receiving recovering from COVID-19 recruited rehabilitation score significantly Symptom TCM the placebo group Tolerance Traditional Chinese medicine Treatment turn two patients with COVID-19 worldwide pandemic
[DOI] 10.1016/j.jep.2021.114830 PMC 바로가기 [Article Type] Randomized Controlled Trial

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

입원하지 않은 환자의 코로나19 경구 치료용 몰누피라비르

Clinical Trial

Published on 2022-02-102022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI 95% confidence interval active against acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse event adverse events All participants Analysis Antiviral assigned baseline baseline characteristics conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 illness death demonstrated diabetes died double-blind early treatment Efficacy and safety efficacy end point end point Enrollment evaluate event Evidence evidence of Hospitalization Hospitalized Imbalance in some incidence interim analysis laboratory-confirmed Mild-to-moderate molnupiravir New oral participant Patient Phase 3 Placebo placebo group placebo-controlled trial progression randomization Randomized Randomly receive reduce reduced reported Result risk risk factor SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 illness Sex Sharp Subgroup analyses subgroups Symptom the placebo group Treatment Trial two groups Viral load was performed
[DOI] 10.1056/NEJMoa2116044 PMC 바로가기 [Article Type] Clinical Trial

Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial

보건 종사자의 Covid-19의 예방에 대한 하이드 록시 클로로 퀴인 : 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-02-092022-09-10
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 assigned baseline clinical trial Complete coronavirus coronavirus disease COVID-19 effect size Effectiveness Efficacy and safety evaluate failure HCQ Health Health care Health care worker health care workers Health personnel high risk hospitalized patient hospitalized patients Hydroxychloroquine lack negative RT-PCR outcome Patient Placebo placebo group placebo-controlled Prophylaxis Randomized randomized clinical trial refusal reported respiratory Result Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 severe acute respiratory syndrome Coronavirus severe COVID-19 severe COVID-19 patients single center statistically significant subject symptomatic infection symptomatic SARS-CoV-2 infection The effect size the placebo group Trial with COVID-19
[DOI] 10.1371/journal.pone.0261980 PMC 바로가기 [Article Type] Randomized Controlled Trial

Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19 A Phase 2 Randomized Clinical Trial

경증에서 중등도의 COVID-19 A 2상 무작위 임상 시험에서 SARS-CoV-2 호흡기 바이러스 제거, 바이러스 배출 및 증상 지속 기간에서 니클로사미드 대 위약의 효능

Randomized Controlled Trial

Published on 2022-02-092022-09-10
Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료제,

[키워드] 1:1 95% CI accounted addition adverse event adverse events age All trial participants analyzed antiviral activity assigned blind by mouth calculated center Chain Reaction Characteristics clearance of SARS-CoV-2 clinical clinical trial confirmation contagious period cough COVID COVID-19 COVID-19 testing decrease determined by diagnose Duration duration of symptom Efficacy enrolled Enrollment exclusion criteria fecal Fecal sample finding group groups headache Headaches Hospitalization Importance in vitro individual Infection intention-to-treat investigators Laboratory Massachusett Massachusetts mean difference mean survival time measure men Mild mild to moderate Mild to moderate COVID-19 mild to moderate symptoms moderate Moderate COVID-19 MONITOR mouth network niclosamide no significant difference objective oral Oropharyngeal participant Participants Patient patients receiving placebo Phase 2 Placebo placebo group placebo-controlled clinical trial platform Point polymerase chain polymerase chain reaction positive primary end point proportion Randomized randomized clinical trial Randomly receive receiving Registration Relevance reported respiratory respiratory sample Respiratory samples Result Safe sample collection Sample size SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 clearance setting shedding significant effect significantly Standard of care statistically Symptom symptom duration symptom resolution Symptoms the placebo group therapy treat Treatment treatment for COVID-19 treatment groups Trial trial participants Tuft vaccination Viral viral clearance viral shedding was collected
[DOI] 10.1001/jamanetworkopen.2021.44942 PMC 바로가기 [Article Type] Randomized Controlled Trial